The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ARCATUS (Arctic Vision Australia Pty Ltd)
Product name
ARCATUS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
252 (255 working days)
Active ingredients
triamcinolone acetonide
Registration type
EOI
Indication
ARCATUS® is indicated for the treatment of macular oedema associated with noninfectious uveitis.